Research Article| Volume 11, ISSUE 4, P373-380, August 1983

Antipsoriatic drugs as inhibitors of soybean lipoxygenase. A possible mode of action

      This paper is only available as a PDF. To read, Please Download here.


      Eight known antipsoriatic drugs of diverse structures were tested on the basis of their structural similarity with arachidonic acid and known inhibitors of lipoxygenase. A correlation was observed between their antipsoriatic activity and lipoxygenase inhibition suggesting that a common underlying mechanism of action might be involved.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Michaelsson G.
        Increased chemotactic activity of neutrophil leukocytes in psoriasis.
        Brit. J. Dermatology. 1980; 103: 351
        • Malmsten C.L.
        • Palmblad J.
        • Uden A.
        • Radmark O.
        • Engstedt L.
        • Samuelsson B.
        Leukotriene-B4: A highly potent and stereospecific factor stimulating migration of polymorphonuclear leukocytes.
        Acts. Physiol. Scand. 1980; 110: 449
        • Bray M.A.
        • Ford-Hutchinson A.W.
        • Smith M.J.H.
        LeukotrieneB4: An inflammatory mediator in vivo.
        Prostaglandins. 1981; 22: 213
        • Bokoch G.M.
        • Reed P.W.
        Effect of various lipoxygenase metabolites of arachidonic acid on degranulation of polymorphonuclear leukocytes.
        J. Biol. Chem. 1981; 256: 5317
        • Bray M.A.
        • Cunningham F.M.
        • Ford-Hutchinson A.W.
        • Smith M.J.H.
        Leukotriene B4: A mediator of vascular permeability.
        Brit. J. Pharm. 1981; 72: 483
        • Björk J.
        • Hedqvist P.
        • Arfors K.
        Increase in vascular permeability induced by Leukotriene B4 and the role of polymorphonuclear leukocytes.
        Inflammation. 1982; 6: 189
        • Goetzl E.J.
        • Woods J.W.
        • Gorman R.R.
        Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid.
        J. Clinical Investigation. 1977; 59: 179
        • Brain S.D.
        • Camp R.D.R.
        • Dowd P.M.
        • Black A.K.
        • Woollard P.M.
        • Mallet A.I.
        • Greaves M.W.
        Psoriasis and Leukotriene B4.
        Lancet. 1982; 762
        • Grabbe J.
        • Czarnetzki B.M.
        • Mardin M.
        Chemotactic Leukotrienes in psoriasis.
        Lancet. 1982; 1464
        • Hammarstrom S.
        • Hamberg M.
        • Samuelsson B.
        • Duell E.A.
        • Stawiski M.
        • Voorhees J.J.
        Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F in epidermis of psoriasis.
        in: 5th Ed. Proc. Natl. Acad. Sci., U.S.A.72. 1975: 5130
        • Hammarstrom S.
        • Lindgren J.A.
        • Marcelo C.
        • Duell E.A.
        • Anderson T.F.
        • Voorhees J.J.
        Arachidonic acid transformations in normal and psoriasic skin.
        J. Investigative Dermatology. 1979; 73: 180
        • Tappel A.L.
        • Lundberg W.O.
        • Boyer P.D.
        Effect of temperature and antioxidants upon the lipoxidase-catalyzed oxidation of sodium linoleate.
        Arch. Biochem. Biophys. 1953; 42: 293
        • Sun F.F.
        • McGuire J.C.
        • Morton D.R.
        • Pike J.E.
        • Sprecher H.
        • Kunau W.H.
        Inhibition of platelet arachidonic acid 12-lipoxygenase by acetylenic acid compounds.
        Prostaglandins. 1981; 21: 333
        • McDonald C.J.
        The uses of systemic chemotherapeutic agents in psoriasis.
        Pharmac. Ther. 1981; 14: 1
        • Elias P.M.
        • Williams M.L.
        Retenoids, cancer, and the skin.
        Arch. Dermatol. 1981; 117: 160
        • Bryant B.G.
        Treatment of psoriasis.
        Am. J. Hosp. Pharm. 1980; 37: 814
        • Hillier K.
        • Castaner J.
        Mycophenolic acid.
        Drugs of the Future. 1978; III: 594
        • Binazzi M.
        • De Panfilis G.
        • Landi G.
        A controlled multicentric study of RO 10-9359 in association with topical corticosteroid therapy in psoriasis.
        Drugs Exptl. Clin. Res. 1981; VII: 57
        • Etretinate
        • Tigasan®
        Drugs of the Future. 1981; VI: 187
      1. The acid (C21H26O3; mp 212–216°C) was characterized by elemental analysis, nmr, ir, and uv.
        • Tappel A.L.
        in: 5th Ed. Methods in Enzymology. V. Academic Press, New York, London1962: 539
        • Smith W.L.
        • Lands W.E.M.
        Oxygenation of unsaturated fatty acids by soybean lipoxygenase.
        J. Biol. Chem. 1972; 247: 1038
        • Gibian M.J.
        • Galaway R.A.
        Steady state kinetics of lipoxygenase oxygenation of unsaturated fatty acids.
        Biochemistry. 1976; 15: 4209
        • Egmond M.R.
        • Veldink G.A.
        • Vliegenthart J.F.G.
        • Boldingh J.
        C-11 H-abstraction from linoleic acid, the rate limiting step in lipoxygenase catalysis.
        Biochem. Biophys. Res. Commun. 1973; 54: 1178
        • Russell D.H.
        • Haddox M.K.
        Antiproliferative effects of Retinoids related to the cell cycle-specific inhibition of ornithine decarboxylase.
        in: Modulation of cellular interaction by Vitamin A and Derivatives (Retinoids) Anals of N.Y. Academy of Sciences. 1981: 281 (V-359)
        • Meyskens Jr., F.L.
        Modulation of abnormal growth by Retinoids: A clinical perspective of the biological phenomenon.
        Life Sciences. 1981; 28: 2323
        • Voorhees J.J.
        • Orfanos C.E.
        Oral Retinoids: Broad-spectrum dermatologic therapy for the 1980's.
        Arch. Dermatol. 1981; 117: 418
        • Schaefer H.
        • Schalla W.
        • Shroot B.
        Pharmacology and Kinetics of Anthralin.
        in: Farber E.M. Cox A.J. Psoriasis-Proceedings of Third Int. Symp., Stanford University Grune and Stratton, New York1981: 111
        • Cashin C.H.
        • Dawson W.
        • Kitchen E.Ann
        The pharmacology of benoxaprofen, (2-[4-Chlorophenyl]-α-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with antiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesis.
        J. Pharm. Pharmacol. 1977; 29: 330
        • Dawson W.
        • Boot J.R.
        • Harvey J.
        • Walker J.R.
        The pharmacology of benoxaprofen with particular reference to effects on lipoxygenase product formation.
        European J. Rheumatology and Inflammation. 1982; 5: 61
        • Allen B.R.
        • Littlewood S.M.
        Benoxaprofen: Effect on cutaneous lesions in psoriasis.
        Brit. Med. J. 1982; 285: 1241
        • Penton D.A.
        • Wilkinson J.D.
        Benoxaprofen: Effect on cutaneous lesions in psoriasis.
        Brit. Med. J. 1982; 285: 1420
        • Hindson C.
        • Lawlor F.
        • Wacks H.
        Benoxaprofen for nodular acne.
        Lancet. 1982; 1415
      2. J.C. Sircar, C.F. Schwender and E.A. Johnson. Soybean Lipoxygenase inhibition by nonsteroidal antiinflammatory drugs. Prostaglandins, in press.

        • Winthrop G.J.
        Does meclofenamate help psoriasis and arthritis?.
        New England J. Medicine. 1982; 307: 1528
        • Kinston W.P.
        15-Lipoxygenase: A rapid, sensitive assay for lipoxygenase inhibitors.
        Brit. J. Pharm. 1981; 74: 919P
        • Harvey J.
        • Parish H.
        • Ho P.P.K.
        • Boot J.R.
        • Dawson W.
        The preferential inhibition of 5-lipoxygenase product formation by benoxaprofen.
        J. Pharm. Pharmacol. 1983; 35: 44